Medline ® Abstract for Reference 108
of 'Complementary and alternative therapies for cancer'
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.
Stephenson CM, Levin RD, Spector T, Lis CG
Cancer Chemother Pharmacol. 2013 Jul;72(1):139-46. Epub 2013 May 14.
PURPOSE: This phase I clinical trial evaluated the safety, tolerability, and pharmacokinetics of high-dose intravenous (i.v.) ascorbic acid as a monotherapy in patients with advanced solid tumors refractory to standard therapy.
METHODS: Five cohorts of three patients received i.v. ascorbic acid administered at 1 g/min for 4 consecutive days/week for 4 weeks, starting at 30 g/m²in the first cohort. For subsequent cohorts, dose was increased by 20 g/m²until a maximum tolerated dose was found.
RESULTS: Ascorbic acid was eliminated by simple first-order kinetics. Half-life and clearance values were similar for all patients of all cohorts (2.0±0.6 h, 21±5 dL/h m², respectively). C(max) and AUC values increased proportionately with dose between 0 and 70 g/m², but appeared to reach maximal values at 70 g/m²(49 mM and 220 h mM, respectively). Doses of 70, 90, and 110 g/m²maintained levels at or above 10-20 mM for 5-6 h. All doses were well tolerated. No patient demonstrated an objective antitumor response.
CONCLUSIONS: Ascorbic acid administered i.v. at 1 g/min for 4 consecutive days/week for 4 weeks produced up to 49 mM ascorbic acid in patient's blood and was well tolerated. The recommended dose for future studies is 70-80 g/m².
Cancer Treatment Centers of America®, Zion, IL 60099, USA.